Open Access

Exploring the latest evidence of cardiovascular benefits with glucagon-like peptide 1 receptor agonists

Event: ESC Congress 2021 - The Digital Experience
Topic: Risk Factors and Prevention
Session type: Satellite Symposium
Sponsored by Novo Nordisk A/S
Date: 27 August 2021
Time: 13:00 - 13:45

Congress Session

This content is currently on OPEN ACCESS

Sign in to view the resources

4 presentations in this session

Glucagon-like peptide 1 receptor agonists & cardiovascular outcomes: What have we learned?

Speaker: Doctor M. Cavender (Chapel Hill, US)
Thumbnail

Cardiovascular effects of glucagon-like peptide 1 receptor agonists.

Speaker: Doctor M. Husain (Toronto, CA)
Thumbnail

Glucagon-like peptide 1 receptor agonist use in cardiology.

Speaker: Professor M. Petrie (Glasgow, GB)
Thumbnail

Live panel discussion.

Thumbnail

3 speakers from this session

Doctor Matthew Cavender

University of North Carolina Hospitals, Chapel Hill (United States of America)
5 presentations
0 follower

Doctor Mansoor Husain

University of Toronto, Toronto (Canada)
7 presentations
1 follower

Professor Mark Petrie

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)
19 presentations
0 follower

This platform is supported by

logo Novo Nordisk